Research ExplorerPublicationsValidation of the revised IPSS at transplant in patients wit...

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party

Standard

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. / Scheid, C; de Wreede, L; van Biezen, A; Koenecke, C; Göhring, G; Volin, L; Maertens, J; Finke, J; Passweg, J; Beelen, D; Cornelissen, J J; Itälä-Remes, M; Chevallier, P; Russell, N; Petersen, E; Milpied, N; Richard Espiga, C; Peniket, A; Sierra, J; Mufti, G; Crawley, C; Veelken, J H; Ljungman, P; Cahn, J Y; Alessandrino, E P; de Witte, T; Robin, M; Kröger, N.

In: BONE MARROW TRANSPL, Vol. 52, No. 11, 11.2017, p. 1519-1525.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Scheid, C, de Wreede, L, van Biezen, A, Koenecke, C, Göhring, G, Volin, L, Maertens, J, Finke, J, Passweg, J, Beelen, D, Cornelissen, JJ, Itälä-Remes, M, Chevallier, P, Russell, N, Petersen, E, Milpied, N, Richard Espiga, C, Peniket, A, Sierra, J, Mufti, G, Crawley, C, Veelken, JH, Ljungman, P, Cahn, JY, Alessandrino, EP, de Witte, T, Robin, M & Kröger, N 2017, 'Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party', BONE MARROW TRANSPL, vol. 52, no. 11, pp. 1519-1525. https://doi.org/10.1038/bmt.2017.171

APA

Scheid, C., de Wreede, L., van Biezen, A., Koenecke, C., Göhring, G., Volin, L., Maertens, J., Finke, J., Passweg, J., Beelen, D., Cornelissen, J. J., Itälä-Remes, M., Chevallier, P., Russell, N., Petersen, E., Milpied, N., Richard Espiga, C., Peniket, A., Sierra, J., ... Kröger, N. (2017). Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. BONE MARROW TRANSPL, 52(11), 1519-1525. https://doi.org/10.1038/bmt.2017.171

Vancouver

Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L et al. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. BONE MARROW TRANSPL. 2017 Nov;52(11):1519-1525. https://doi.org/10.1038/bmt.2017.171

Bibtex

@article{82b58e0b032f4b4190aba7c4a20b63ba,
title = "Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party",
abstract = "The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P<0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P<0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.Bone Marrow Transplantation advance online publication, 11 September 2017; doi:10.1038/bmt.2017.171.",
keywords = "Journal Article",
author = "C Scheid and {de Wreede}, L and {van Biezen}, A and C Koenecke and G G{\"o}hring and L Volin and J Maertens and J Finke and J Passweg and D Beelen and Cornelissen, {J J} and M It{\"a}l{\"a}-Remes and P Chevallier and N Russell and E Petersen and N Milpied and {Richard Espiga}, C and A Peniket and J Sierra and G Mufti and C Crawley and Veelken, {J H} and P Ljungman and Cahn, {J Y} and Alessandrino, {E P} and {de Witte}, T and M Robin and N Kr{\"o}ger",
year = "2017",
month = nov,
doi = "10.1038/bmt.2017.171",
language = "English",
volume = "52",
pages = "1519--1525",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "11",

}

RIS

TY - JOUR

T1 - Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party

AU - Scheid, C

AU - de Wreede, L

AU - van Biezen, A

AU - Koenecke, C

AU - Göhring, G

AU - Volin, L

AU - Maertens, J

AU - Finke, J

AU - Passweg, J

AU - Beelen, D

AU - Cornelissen, J J

AU - Itälä-Remes, M

AU - Chevallier, P

AU - Russell, N

AU - Petersen, E

AU - Milpied, N

AU - Richard Espiga, C

AU - Peniket, A

AU - Sierra, J

AU - Mufti, G

AU - Crawley, C

AU - Veelken, J H

AU - Ljungman, P

AU - Cahn, J Y

AU - Alessandrino, E P

AU - de Witte, T

AU - Robin, M

AU - Kröger, N

PY - 2017/11

Y1 - 2017/11

N2 - The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P<0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P<0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.Bone Marrow Transplantation advance online publication, 11 September 2017; doi:10.1038/bmt.2017.171.

AB - The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P<0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P<0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.Bone Marrow Transplantation advance online publication, 11 September 2017; doi:10.1038/bmt.2017.171.

KW - Journal Article

U2 - 10.1038/bmt.2017.171

DO - 10.1038/bmt.2017.171

M3 - SCORING: Journal article

C2 - 28892084

VL - 52

SP - 1519

EP - 1525

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 11

ER -